PDCD6 additively cooperates with anti-cancer drugs through activation of NF-kappa B pathways
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sung Ho | - |
dc.contributor.author | Lee, Jeong Heon | - |
dc.contributor.author | Lee, Gwang-Beom | - |
dc.contributor.author | Byun, Hyun-Jung | - |
dc.contributor.author | Kim, Boh-Ram | - |
dc.contributor.author | Park, Chan-Yong | - |
dc.contributor.author | Kim, Hong-Bae | - |
dc.contributor.author | Rho, Seung Bae | - |
dc.date.available | 2020-02-29T06:44:47Z | - |
dc.date.created | 2020-02-05 | - |
dc.date.issued | 2012-03 | - |
dc.identifier.issn | 0898-6568 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16545 | - |
dc.description.abstract | The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues. In the current study, we characterized the specific function of PDCD6 as a novel pro-apoptotic protein. To define the roles of PDCD6 and cisplatin in tumorigenesis, we either over-expressed PDCD6 or treated it with cisplatin in SKOV-3 ovarian cancer cells. Both PDCD6 and cisplatin respectively inhibited cancer cell proliferation in a dose-dependent manner. The combined treatment of PDCD6 and cisplatin was more effective at suppressing cell growth than with either drug treatment alone, but had no effect with the treatment of caspase-3 and caspase-9 inhibitors. Cleavages of caspase-3, -8, -9, and poly (ADP-ribose) polymerase (PARP) in PDCD6-overexpressing cells were significantly increased after cisplatin treatment. Cell cycle analysis highly correlated with down-regulation of cyclin D1 and CDK4, and the induction of p16 and p27 as a cyclin-dependent kinase inhibitor. Additionally. PDCD6 also suppressed the phosphorylation of signaling regulators downstream of PI3K, including PDK1 and Akt. PDCD6 promotes TNF alpha-dependent apoptosis through the activation of NF-kappa B signaling pathways, increasing Bax, p53, and p21 expression, while also down-regulating Bcl-2 and Bcl-xL expression. The p21 and p53 promoter luciferase activities were enhanced by PDCD6, while there was no affect in p53(-/-) and p21(-/-). At the same time, p53 activity was confirmed by UV irradiation and siPDCD6. Taken together, these results provide evidence that PDCD6 can mediate the proapoptotic activity of cisplatin or TNF alpha through the down-regulation of NF-kappa B expression. (C) 2011 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.isPartOf | CELLULAR SIGNALLING | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | APOPTOSIS | - |
dc.subject | ALG-2 | - |
dc.subject | GENE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | CARBOPLATIN | - |
dc.subject | OXALIPLATIN | - |
dc.subject | EVOLUTION | - |
dc.subject | CARCINOMA | - |
dc.title | PDCD6 additively cooperates with anti-cancer drugs through activation of NF-kappa B pathways | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000300478400016 | - |
dc.identifier.doi | 10.1016/j.cellsig.2011.11.006 | - |
dc.identifier.bibliographicCitation | CELLULAR SIGNALLING, v.24, no.3, pp.726 - 733 | - |
dc.identifier.scopusid | 2-s2.0-84855585741 | - |
dc.citation.endPage | 733 | - |
dc.citation.startPage | 726 | - |
dc.citation.title | CELLULAR SIGNALLING | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Lee, Gwang-Beom | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Tumor suppressor protein | - |
dc.subject.keywordAuthor | Programmed cell death 6 | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Ovarian tumorigenesis | - |
dc.subject.keywordAuthor | Cell cycle | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | NF-kappa B signalling | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | ALG-2 | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARBOPLATIN | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | EVOLUTION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.